Simplified Methods for Quantification of ¹⁸F-Fluoromethylcholine Uptake: Is SUV_{AUC,PP} Actually an SUV?

TO THE EDITOR: Verwer et al. (1) recently presented a study aimed at validating the use of simplified methods for quantification of ¹⁸F-fluoromethylcholine uptake in a routine clinical setting of prostate cancer patients. The authors nicely demonstrated that ¹⁸F-fluoromethylcholine uptake should be quantified using full kinetic modeling involving a single-tissue-compartment model with irreversible trapping and a blood volume parameter, in combination with a metabolite-corrected plasma input function based on invasive arterial blood sampling. The authors proposed—as a noninvasive simplified method based on 2 consecutive static PET scans—the use of the ratio (SUV_{AUC,PP}) of lesion activity concentrations (A_L(t), assessed 30-40 min after injection) normalized to the area under the curve of the metabolite-corrected plasma input function (AUC_{PP}, computed over 0-30 min after injection). This ratio provided an excellent correlation to the uptake rate constant of the full kinetic modeling (Fig. 6C; SUV_{AUC,PP} = $14.54 \times K_1 + 0.02$; $R^2 = 0.91$) (1).

We would like to point out that the slope of the fit reveals a discrepancy of 14.54 between $SUV_{AUC,PP}$ and K_1 , whereas SUV_{AUC,PP} should be considered as a noninvasive surrogate for K_1 and a slope around 1 should be expected. Indeed, as previously shown by Patlak (2), $K_1 = A_L(t)/AUC_{PP}$, which is actually the $SUV_{AUC,PP}$ definition. Therefore, corrections to the $SUV_{AUC,PP}$ outcomes reported by Verwer et al. may be proposed for a better comparison with K_1 . For this comparison, an analytic expression for AUCPP and hence for SUVAUCPP, as simple as possible, is needed to clarify the unit of each parameter. Let us assume that the metabolite-corrected plasma input function monoexponentially decays with a (decay-corrected) time constant α : then AUC_{PP} = $A_0/\alpha \times [1 - \exp(-\alpha T)]$, with T = 30 min and A_0 the initial (virtual) metabolite-corrected plasma activity concentration (3). AUC_{PP} is the total number of disintegrations per milliliter (of blood) that have occurred over the time range 0-T; A₀ is expressed in Bq/mL, that is, number of disintegrations per second and per milliliter; [1 - exp $(-\alpha T)$] has no dimension; α is expressed in s⁻¹ because A₀ involves becquerels (i.e., equivalent to s⁻¹). Finally, SUV_{AUC,PP} is expressed in s⁻¹ because of the A_L(t) unit, which is Bq/mL. To consistently compare $SUV_{AUC,PP}$ and K_1 , we suggest that 2 corrective factors should be applied. First, because in current practice A_L(t) is usually expressed in kBq/mL rather than in Bq/mL, A₀ should then be expressed in kBq/mL instead of in MBq/mL, as indicated in Figure 6C (and in Supplemental Fig. 2C) (1): the corrective factor is 1/1,000. Second, because K_1 is usually expressed in min⁻¹ rather than in s⁻¹ (the axis units in Fig. 6C and supplemental Fig. 2C are not clearly indicated), the corrective factor is 60. As a result, we suggest that the SUV_{AUC.PP} outcomes reported by Verwer et al. should be multiplied by a corrective factor of 60/1,000, leading to a further slope of 0.87 instead of 14.54 in Figure 6C.

In conclusion, Verwer et al. convincingly demonstrated that, instead of SUV, SUV_{AUC,PP} could be used in current clinical practice to noninvasively quantify ^{18}F -fluoromethylcholine uptake in prostate cancer patients. We further suggest that SUV_{AUC,PP} is actually an uptake rate constant rather than an SUV (usually expressed in min^{-1} and g/mL, respectively) and that the above-proposed correction strengthens its relevance.

REFERENCES

- Verwer EE, Oprea-Lager DE, van den Eertwegh AJ, et al. Quantification of ¹⁸Ffluorocholine kinetics in patients with prostate cancer. *J Nucl Med.* 2015;56: 365–371.
- Patlak CS. Derivation of equations for the steady-state reaction velocity of a substance based on the use of a second substance. J Cereb Blood Flow Metab. 1981;1:129–131.
- Laffon E, de Clermont H, Marthan R. A method of adjusting SUV for injectionacquisition time differences in ¹⁸F-FDG PET imaging. Eur Radiol. 2011;21: 2417–2424.

Eric Laffon*
Henri de Clermont
Roger Marthan

*Hôpital du Haut-Lévèque Avenue de Magellan 33604 Pessac, France E-mail: elaffon@u-bordeaux2.fr

Published online May 29, 2015. DOI: 10.2967/jnumed.115.160812

REPLY: We would like to thank Laffon and coworkers for their interest in our paper (I), as well as for their valuable comments and for giving us the opportunity to further clarify our results.

In our paper we aimed to find a simplified method for quantification of ¹⁸F-fluoromethylcholine uptake. The most common simplified metric to quantify tracer uptake is the standardized uptake value (SUV), which represents tracer concentration at a certain time normalized to injected activity and a factor representing distribution volume (e.g., weight, lean body mass, or body surface area). This normalization is used as a surrogate for the integrated availability of the radiotracer to the tumor.

One of the aims of full kinetic analysis is to identify and validate these simplified methods or normalization factors. In our study, we found that commonly used normalization factors such as injected activity per weight, lean body mass, or body surface area were not appropriate surrogates for the integrated availability of the radiotracer to the tumor, that is, the integral of the input function. Therefore, we proposed a dual-scan procedure in which the first scan is used to directly measure this integral, which is then used to normalize tracer uptake measured in the second scan. We would argue that the unit of the normalization factor does not qualify or disqualify the simplified measure from being termed an SUV, since commonly used normalization factors such as body weight or body surface area also yield SUV in different units.

Nevertheless, the authors are correct in their observation that we have not consistently used the same units in nominators and denominators of the relevant equations and we could have been

COPYRIGHT @ 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.